Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

5.900 +0.020 (+0.34%)
Streaming Delayed Price Updated: 2:43 PM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,822
Open 6.030
Bid (Size) 5.770 (3)
Ask (Size) 5.990 (1)
Prev. Close 5.880
Today's Range 5.750 - 6.030
52wk Range 4.650 - 10.24
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
From Coya Therapeutics, Inc.
Via Business Wire

Performance

YTD
+3.3%
+3.3%
1 Month
-2.5%
-2.5%
3 Month
-9.8%
-9.8%
6 Month
-5.3%
-5.3%
1 Year
-16.9%
-16.9%

More News

Read More
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025
From Coya Therapeutics, Inc.
Via Business Wire
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Coya Therapeutics Announce Positive Interim Result from Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
Via Get News
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)
From Coya Therapeutics, Inc.
Via Business Wire
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
Via Benzinga
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
From Coya Therapeutics, Inc.
Via Business Wire
EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases
Via Benzinga
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
From Coya Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Coya Therapeutics, Inc. - Common Stock publicly traded?
Yes, Coya Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Coya Therapeutics, Inc. - Common Stock trade on?
Coya Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Coya Therapeutics, Inc. - Common Stock?
The ticker symbol for Coya Therapeutics, Inc. - Common Stock is COYA on the Nasdaq Stock Market
What is the current price of Coya Therapeutics, Inc. - Common Stock?
The current price of Coya Therapeutics, Inc. - Common Stock is 5.900
When was Coya Therapeutics, Inc. - Common Stock last traded?
The last trade of Coya Therapeutics, Inc. - Common Stock was at 06/09/25 02:43 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.